A Call to Share Your EGCG Experiences With BioNews Insights

Charlene Marshall avatar

by Charlene Marshall |

Share this article:

Share article via email
mold, anxiety, appointments, Rare Disease Day, patient experience, wish list, goals, community, IPF cough, anxiety, holiday season, life lessons, story, cold temperatures, toxic positivity, peer support, before and after, exercise, power outages, productivity

Have you ever suddenly realized you are part of something special?

This happened to me today during a video call with other members of the BioNews Insights (BNI) team. BNI is a relatively new division of our company, BioNews, focused on market research. The team is small, but this morning, we had six people on our call, four of them representing different rare diseases, which felt really special.

I’d like to echo some of the sentiments from a previous column from a woman with SMA, titled “What Working at BioNews Has Taught Me.” Becoming a columnist and writing about my experience as a young adult with IPF has been incredibly rewarding in more ways than I can count. Everyone at BioNews is invested in rare disease patients, but what makes this company so special is how our voices are truly valued.

I’ve spoken to many in the PF community who feel their voice is rarely heard when it comes to their medical care, advocacy efforts, or opinions about things that could make living with this life-threatening lung disease easier. This is not the case at BioNews, and I am grateful that our collective voice as rare disease patients is honored here.

Last January, I wrote a column about how being vulnerable as a chronically ill patient can be beneficial. I detailed many opportunities I’ve had as a result of sharing my story and becoming a patient advocate for others with PF. I’m grateful to have affected others, but I also can’t neglect how becoming part of the BioNews team has helped me. My role as a columnist and moderator of the Pulmonary Fibrosis News Forums has been therapeutic, as being able to help others motivates and inspires me. It’s helped me cope with the grim prognosis of this disease and given me something to do about my diagnosis.

Now, as part of the BNI research team, I have the opportunity to do even more work for the PF community, alongside a team of other patients, researchers, and BioNews staff. We’re almost ready to launch a longitudinal survey about PF patients’ experiences with epigallocatechin gallate, or EGCG, an organic compound in green tea that is believed to have several health benefits. EGCG has been a popular topic at our forums, particularly since The New England Journal of Medicine published an interesting study about it earlier this year. In that study, EGCG appeared to be associated with lower levels of fibrotic markers in patients who were given it.

While BNI does not have the ability to conduct a clinical trial of EGCG, we are excited to learn about the experiences of patients who use it via a survey. More information about how we plan to do this can be found at the forums, and we’re grateful to everyone who has expressed interest in our experimental group thus far.

Our call to action is unique, and before we get started, we need additional control participants for the project, specifically patients who are not taking EGCG, Ofev (nintedanib), or Esbriet (pirfenidone). If you might be able to help us, please read this forum post about how to connect.

Members of the BNI team hope that documenting the experiences of PF patients taking EGCG will prompt further conversation about it.

We are excited to see what kind of information this project will generate. However, we want to make it clear that we are not recommending patients start or stop taking EGCG, nor will we provide guidance about dosage. Those types of decisions are up to you and your healthcare team. This project is observational, and we hope it will generate discussion between members of the PF community, physicians, and researchers.

Thank you in advance for helping us with this project!

***

Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Pulmonary Fibrosis News or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to pulmonary fibrosis.

Comments

Janice Shabra avatar

Janice Shabra

I'm not sure what the longitudinal survey would include,
but I am not on OFV nor Esbriet and have been taking Teavigo Green Tea Extract, 600mg of EGCG (Swansons decaf) for two weeks.

Reply
Charlene Marshall avatar

Charlene Marshall

Hi Janice,

Thank you so much for getting in touch regarding our EGCG project. I really appreciate it, and based on your experience, you'd be a great fit for our experimental group. I'd love to provide you with more information on the project, and our BioNews Research Team can do that. May I have your permission to share your email with them? From there, Jenn P or Jen C will be in touch with you regarding next steps, or to answer any questions you may have. It is always important for me to first obtain permission before ever sharing personal information, such as an email. :)

Feel free to connect with me directly if that is easier: [email protected]

Sincerely,
Char.

Reply
Steve Dragoo avatar

Steve Dragoo

Hi Charlene - I have been taking NOW brand EGCG 400 mg in the AM 200 mg PM for over a month. I believe it has helped but I probably need to understand how/when to take it more clearly. If I can help please let me know. You have my email and can share it as needed. Stay well - Steve

Reply

Leave a comment

Fill in the required fields to post. Your email address will not be published.